Agha Rania, Heysek Randy V, Vasily David B, Rowe Russell, McClure Erin M, O'Reilly Kathryn, Finkelstein Steven Eric, Farberg Aaron S
Department of Dermatology, University of Illinois at Chicago, Chicago, IL 60612, USA.
Jesse Brown VA Medical Center, Chicago, IL 60612, USA.
J Clin Med. 2024 Sep 30;13(19):5835. doi: 10.3390/jcm13195835.
: Basal cell carcinomas (BCCs) and squamous cell carcinomas (SCCs) are non-melanoma skin cancers (NMSCs) and the most prevalent cancers in the United States. Image-guided superficial radiotherapy (IGSRT) is a relatively new treatment option that uses high-resolution dermal ultrasound integrated with superficial radiotherapy to improve tumor visualization. IGSRT is a clinically equivalent non-surgical alternative to Mohs micrographic surgery at 2 years of follow-up in early-stage NMSC, but larger cohort studies with longer follow-up periods that allow for analysis of patient outcomes by demographic and disease characteristics are needed. : This large, retrospective cohort study was conducted to determine the effect of risk factors (tumor location, tumor stage, and sex) on 2-, 4-, and 6-year freedom from recurrence rates in 19,988 NMSC lesions treated with IGSRT, including lesions with complete treatment courses. : Overall freedom from recurrence rates were 99.68% at 2 years, 99.54% at 4 years, and 99.54% at 6 years; rates did not differ significantly by tumor location (head/neck versus other locations, = 0.9) or sex (male versus female, = 0.4). In contrast, there was a significant difference in freedom from recurrence rates when analyzed by tumor stage ( = 0.004). : There was no significant effect of tumor location or sex on freedom from recurrence in IGSRT-treated NMSC. Although there was a significant difference according to tumor stage, freedom from recurrence rates exceeded 99% at all stages.
基底细胞癌(BCC)和鳞状细胞癌(SCC)是非黑色素瘤皮肤癌(NMSC),也是美国最常见的癌症。图像引导下的浅表放射治疗(IGSRT)是一种相对较新的治疗选择,它使用高分辨率皮肤超声与浅表放射治疗相结合,以改善肿瘤可视化。在早期NMSC的2年随访中,IGSRT在临床上等同于莫氏显微外科手术的非手术替代方法,但需要进行更大规模的队列研究,且随访期更长,以便按人口统计学和疾病特征分析患者的预后。:这项大型回顾性队列研究旨在确定风险因素(肿瘤位置、肿瘤分期和性别)对19988例接受IGSRT治疗的NMSC病变(包括完成整个治疗疗程的病变)2年、4年和6年无复发生存率的影响。:总体无复发生存率在2年时为99.68%,4年时为99.54%,6年时为99.54%;按肿瘤位置(头颈部与其他部位,P = 0.9)或性别(男性与女性,P = 0.4)分析,生存率无显著差异。相比之下,按肿瘤分期分析时,无复发生存率存在显著差异(P = 0.004)。:在接受IGSRT治疗的NMSC中,肿瘤位置或性别对无复发生存率没有显著影响。虽然根据肿瘤分期存在显著差异,但所有分期的无复发生存率均超过99%。